Prosecution Insights
Last updated: November 20, 2026
Application No. 17/795,895

METHODS FOR DETECTING FOOD ALLERGIES

Non-Final OA §112
Filed
Jul 28, 2022
Priority
Feb 27, 2020 — provisional 62/982,273 +2 more
Examiner
TRAN, CHAU NGUYEN BICH
Art Unit
1677
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Regents of the University of Michigan
OA Round
3 (Non-Final)
32%
Grant Probability
At Risk
3-4
OA Rounds
0m
Est. Remaining
77%
With Interview

Examiner Intelligence

Grants only 32% of cases
32%
Career Allowance Rate
24 granted / 76 resolved
-28.4% vs TC avg
Strong +45% interview lift
Without
With
+45.2%
Interview Lift
resolved cases with interview
Typical timeline
4y 0m
Avg Prosecution
26 currently pending
Career history
116
Total Applications
across all art units

Statute-Specific Performance

§101
11.6%
-28.4% vs TC avg
§103
43.4%
+3.4% vs TC avg
§102
10.2%
-29.8% vs TC avg
§112
22.6%
-17.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 76 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 06/11/2026 has been entered. Priority The present application was filed on 07/28/2022. This application is a 371 of PCT/US21/19801 filed on 02/26/2021 which claims benefit under 35 U.S.C. 119(e) to U.S. Provisional Patent Application 62/982,273 filed on 02/27/2020. Claim status Claims 1 and 3 are cancelled. Claims 2, and 4-10 are pending and examined herein. Withdrawn Objections/Rejection The previous rejection of claims 2 and 4-10 under USC 103 is withdrawn in view of the Applicant’s argument. New ground of rejection is made. Drawings The drawings are objected to because Fig.3C contains informalities. Fig.3C: the 30 kDa size mark on the right side is not consistent with the 35 kDa size mark on the left side (see on the left, the higher value appears to be shown lower than the lower value). Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 2 and 4-10 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is the enablement rejection. Claim 2 recites a method of treating a food allergy in a subject. The method comprises determining the presence of one or more fragments of the desmoglein-2 (DSG-2) protein in a sample obtained from the subject using an immunoassay, wherein the presence of one or more fragments of the DSG-2 protein indicates that the subject has a food allergy. The method comprises administering an antihistamine, epinephrine, oral immunotherapy, sublingual immunotherapy, and/or epicutaneous immunotherapy to the subject, whereby the food allergy is treated. Claim 5 depends from claim 2. Claim 5 recites determining the presence of a 22 kDa DSG-2 protein fragment, a 30 kDa DSG-2 protein fragment, and/or a 75 kDa DSG-2 protein fragment. Claim 10 depends on claim 2. Claim 10 recites the sample is urine or blood. The breadth of the claim The claim encompasses that the presence of one or more DSG-2 fragments in a sample of a subject indicates the subject has food allergy. The claim encompasses administering the treatments for food allergy (an antihistamine, epinephrine, oral immunotherapy, sublingual immunotherapy, and/or epicutaneous immunotherapy) to a subject who has one or more fragments of the DSG-2 protein in a sample obtained from the subject. The independent claim encompasses detecting DSG-2 fragments in any type of samples, dependent claim 10 limited to sample that is urine or blood. The independent claim encompasses detecting DSG-2 fragments in any sizes, dependent claim 5 limited to a 22 kDa DSG-2 protein fragment, a 30 kDa DSG-2 protein fragment, and/or a 75 kDa DSG-2 protein fragment. The nature of the invention Severe food allergy-related reactions, also known as food-triggered anaphylaxis, are serious life threatening reactions. Multiple organ systems, including gastrointestinal (GI), often develop anaphylaxis following exposure to the dietary allergen. GI symptoms occur in as many as 40% cases, and link to more severe anaphylactic phenotypes. However, the molecular processes that regulate the gastrointestinal (GI) response are not as well-defined. The invention is directed to the biomarkers for diagnosing and treating food allergies in susceptible individuals. See specification paragraphs 4-5. The biomarkers are fragments of adherence junction proteins which are derived from the response of a small intestine tissue following food allergen exposure. See specification paragraph 15. The invention detects the presence of one or more fragments of the desmoglein-2 (DSG-2) protein in a food-induced anaphylactic reaction in an animal model. See specification paragraphs 27-31. Pretreatment subjects with immunotherapy before food challenge reduced the incidence of diarrhea in the subjects following the 7th OVA-challenge (see specification par.73). The state of the prior art Ungewiß (Desmoglein 2 regulates the intestinal epithelial barrier via p38 mitogen-activated protein kinase, Scientific Reports 7: 6329, 2016) teaches desmoglein (Dsg) is an adhesion molecule of desmosomes which serves as an intercellular junctional on intestinal epithelial cells (see Abstract and page 1 par.1). Dsg2 is the only Dsg isoform expressed in enterocytes which is the columnar epithelium of the human intestine (see Abstract and page 1 par.1). Dsg2 is known to play a role in inflammation and in the pathogenesis of Crohn’s disease as it mediates signaling events (see page 2 par.1). Dsg2, beside its adhesion function, regulates intestinal barrier function via p38MAPK signaling (see Abstract). Zuckerman (Pathophysiology of nasal polyposis: The role of desmosomal Junctions, Am J Rhinol 22, 589–597, 2008, PTO-892 02/13/2026) teaches that Dsg2 protein fragments are detected in the nasal tissue of the patients with allergic rhinitis (see page 592 col.2 par.2 and Fig.2). Zuckerman teaches that inflammatory cytokines affect the expression of Dsg2 and the cleavage of Dsg2 (see Abstract, Fig.5b, and Fig.6b). IL-13 and IFN-gamma show evidence of Dsg2 protein cleavage by Western blot (see Abstract, Fig.5b, and Fig.6b). Zuckerman determines the presence of the Dsg2 protein in a sample obtained from the subject using an immunoassay (see page 591 col.1 Subjects and Immunofluorescence, and Fig.1). The Dsg2 fragments are detected in cell culture and tissue samples (see Fig.5). While Zuckerman shows the presence of one or more fragments of Dsg2 in allergic rhinitis, allergic rhinitis is not necessarily always related to food allergens. For example, it is commonly caused by inhalant allergens, e.g., pollens, molds, animal dander, and dust mites. See Skoner (Allergic rhinitis: Definition, epidemiology, pathophysiology, detection, and diagnosis, J Allergy Clin Immunol Volume 108, Number 1). Kamekura (Inflammation-induced esmoglein-2 ectodomain shedding compromises the mucosal barrier, MBoC vol.26 Sept 2015, PTO-892 06/20/2025) teaches that the shedding of DSG-2 of the mucosal barrier (e.g., in intestinal epithelial cells) is induced by proinflammatory cytokines in ulcerative colitis (see Title and Abstract). In particular, IL-1β and TNF-α induce Dsg2 cleavage in intestinal epithelial cells (IECs), generating 25- and 100-kDa extra-cellular domain (EC) fragments (see page 3166 column 1 paragraph 2). Kamekura teaches that the shedding of Dsg2, and E-cadherin increased with proinflammatory cytokines, e.g., TNF-α (see 3171 col.2 par.3 and Fig.5C). Kamekura teaches that the fragments of the Dsg2 protein in a sample are detected using an immunoassay. (See Fig.5 and page 3175 section Human colon samples, and page 3173 section Cell and organ culture). The Dsg2 fragments are detected in serum, cell culture, and tissue samples (see Fig.4, page 3173 col.1 par.2). Nava (Cleavage of transmembrane junction proteins and their role in regulating epithelial homeostasis, Tissue Barriers 1:2, e24518, 2013) teaches the influence of junction protein cleavage products on pathogenesis of inflammation and cancer (see Abstract). In particular, Dsg2 protein cleavage is observed in human colon tissue, which contributes to the detachment of the dead cells observed in epithelial tissues, or promotes apoptosis in the intestinal epithelium, or promotes cell proliferation. Dsg2 may also be responsible for the regulation of several mitogenic signaling pathways (see page 9 col.1 par.2-3). Dsg2 protein fragments are also detected during cancer development (see page 6 col.2 par.1). Cleavage of Dsg2 in intestinal epithelial cells by matriptase has been associated with decreased cancer cell–cell adhesion (see page 6 col.2 par.1). Burks (Treatment for food allergy, J Allergy Clin Immunol, 2018) provides a plurality of food immunotherapy including oral, sublingual, and epicutaneous delivery routes (see Abstract). The efficacy of the treatment methods are in the same order as their side effects (see Abstract, Conclusion). The side effects include induction of episodic anaphylaxis with dosing, dose-limiting gastrointestinal side effects in approximately 20%, and eosinophilic esophagitis in less than 5% of clinical trial participants (see page 5). The side effects also include oropharyngeal itching or tingling (see page 5). The level of predictability in the art The role of junction protein cleavage products, e.g., Dsg2, in the pathogenesis of inflammation and cancer has been known. The prior arts teach that the presence of one or more Dsg2 protein fragments relates to inflammation, Crohn’s disease and cancer (see Ungewiß, Zuckerman, Kamekura, and Nava). Dsg2 may also be responsible for the regulation of several mitogenic signaling pathways (see Nava). The cleavage of Dsg2 protein is induced following the proinflammatory cytokine exposure of mucosa tissues (see Zuckerman, Kamekura). The cleavage of Dsg2 is found in cancer tissues (see Nava, Kamekura). The cleavage of Dsg2 is found in nasal mucosa tissues in subjects with allergic rhinitis, which is a type of allergy caused by inhalant allergen (see Zuckerman, Skoner). Dsg2 fragments are detected in tissue, cell culture supernatant, and blood (see Zuckerman, Kamekura). However, the prior arts do not teach the relationship between food allergy and the cleavage of Dsg2 protein. The prior arts do not support the administration of antihistamine, epinephrine, oral immunotherapy, sublingual immunotherapy, and/or epicutaneous immunotherapy on the subject having one or more Dsg2 fragments. Therefore, the link between the presence of one or more Dsg2 fragments and food allergy is not predictable based on the prior art. Accordingly, the administration of food allergy treatment to subjects having one or more Dsg2 fragments is not predictable, as the presence of such Dsg2 fragments does not reliably establish if a subject has a food allergy. While the food allergy treatment may be effective in subjects with a confirmed food allergy (see Burks), its potential therapeutic benefits must be weighed against the associated adverse effects, which may be of comparable magnitude (see Burks). If a subject does not have a food allergy but nevertheless exhibits one or more Dsg2 fragments in the sample due to other causes, the benefits of administering food allergy treatment to the subject are unclear. Furthermore, the subject may be exposed to unnecessary adverse effects associated with the therapy (see Burks). The existence of working examples and the quantity of experimentation necessary Example 3 demonstrates that direct exposure of OVA to jejunal SI preparations is sufficient to promote epithelial transcellular and paracellular dysfunction. Example 3 shows a significant reduction in the level of full length transmembrane proteins including E-cadherin and desmoglein-2 (Dsg2). Example 3 also shows cleaved fragments of the AJ protein, E-cadherin (˜55 kDa), Dsg2 (22 kDa), and Dsc-2 (75 kDa) in subjects at 7th challenge. See paragraphs 67. The samples used in example 3 are SI epithelial extracts from anaphylactic mice. Example 3 also determines whether a single dietary antigen-challenge induced rapid SI cadherin cleavage. To do this, Si epithelial Dsg2 was examined in mice prior to (Pre-) and following (Post-) the 7th food-challenge. The loss of the native full length Dsg2 was observed following the 7th challenge. Also there were decreased levels of the 50 kDa Dsg2 cleavage fragment and accumulation of a lower molecular weight (30 kDa) Dsg2 fragment (FIG. 3C). See paragraph 69. Example 4 shows that the pretreatment with immunotherapy on the food challenged subjects reduced the incidence of diarrhea in the subjects following the 7th OVA-challenge (see par.73). Applicant’s working examples demonstrates that Dsg2 fragment profile of subject with food allergen challenge is different from that of subject without food allergen challenge (Fig.3). Example 3 shows the presence of 22 kDa or 30 kDa Dsg2 fragments in subjects with food allergen challenge. These specific fragments are not shown in subjects without food allergen challenge. The data do not show the presence of 75 kDa Dsg2 fragments in subjects either with or without food allergen challenge. The Dsg2 fragment profile is conducted on SI epithelial extracts. No working example is done in the blood or urine of subjects with a food allergen challenge. It would require undue experimentation for one of skill in the art make and use the inventions as claim, because the prior arts show that Dsg2 fragments are also detected in subjects with other inflammation or cancer. The fragments of Dsg2 taught in the prior arts are in different sizes. The prior arts support the presence of Dsg2 in a variety of samples including cell lysates and blood. However, the prior arts do not specifically teach the 22 kDa Dsg2 fragment, 30 kDa Dsg2 fragment and 75 kDa Dsg2 fragments. The specification does not compare the presence or absence of at least one Dsg-2 fragment (or at least one Dsg-2 fragment in claim 5) across subjects with different health conditions (e.g., food allergy, inflammation, and cancer). Put another way, upon detecting fragments as claimed, based on the cited art of record, it is not predictable that one having ordinary skill would be able to determine whether a subject should be administered treatment as claimed, or if instead the subject is exhibiting the claimed fragments as a result of inflammation caused by something other than food allergy or cancer. Also, the specification does not detect Dsg2 fragments (or at least one Dsg-2 fragment in claim 5) in common subjects with unknown health condition to demonstrate the ability to use Dsg2 fragments in diagnosing food allergies. The specification does not detect Dsg-2 fragments in the blood or urine of subjects with a food challenge either. While the data in the specification show the presence of one or more Dsg2 fragments in subjects having food allergy, the data are not sufficient to support the unique link between Dsg2 fragments and food allergy or the need to treat a subject for food allergy as claimed. The presence of one or more Dsg2 fragments in a sample obtained from a subject does not indicate whether the subject has a food allergy. The data in the specification do not support the detection of Dsg2 fragments in any type of samples because no working example is done in the blood or urine. Further, based on the prior art, it is also not predictable that all of the claimed fragments are present and present in detectable levels in the urine or blood, let alone in the urine or blood as related to the need to treat a food allergy. The data in the specification are not sufficient to support administering the treatments for food allergy (an antihistamine, epinephrine, oral immunotherapy, sublingual immunotherapy, and/or epicutaneous immunotherapy) to a subject who has one or more fragments of the DSG-2 protein in a sample obtained from the subject. The level of ordinary skill in the art Based on what was known in the prior art and the breadth of the invention which involves detecting and treating based on an immune response, the level of skill in the art is high. In summary, there is a lack of disclosure in the art as well as insufficient description in the specification regarding a correlation between Dsg2 fragments (or at least one Dsg-2 fragment in claim 5) and food allergy, or how to use the claimed fragments to determine food allergy and subsequent administration of the claimed treatments. The specification does not enable any one of ordinary skill in the art to use the invention commensurate in scope that the presence of 75 kDa Dsg2 alone or in combination with other claimed Dsg2 fragments indicates a subject with food allergy, because the specification does not show a 75 kDa Dsg2 in a subject with food allergy. Therefore, the specification does not enable any one of ordinary skill in the art to use the claimed invention. Response to Arguments Applicant's arguments filed 06/11/2026 regarding the rejections under 35 USC 103 have been fully considered and persuasive. The rejections under 35 USC 103 are withdrawn. Conclusion Although claims 2 and 4-10 appear to be free of the prior art, the claims are rejected under 35 U.S.C. 112 (a), regarding enablement. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHAU N.B. TRAN whose telephone number is (571)272-3663. The examiner can normally be reached Mon-Fri 8:30-6:30 CT. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bao-Thuy L Nguyen can be reached at 571-272-0824. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHAU N.B. TRAN/ Examiner, Art Unit 1677 /ELLEN J MARCSISIN/ Primary Examiner, Art Unit 1677
Read full office action

Prosecution Timeline

Jul 28, 2022
Application Filed
Jun 20, 2025
Non-Final Rejection mailed — §112
Sep 22, 2025
Response Filed
Dec 20, 2025
Final Rejection (signed) — §112
Feb 13, 2026
Final Rejection mailed — §112
Jun 11, 2026
Request for Continued Examination
Jun 12, 2026
Response after Non-Final Action
Nov 12, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12693290
INTERFERENCE-SUPPRESSED PHARMACOKINETIC IMMUNOASSAY
4y 8m to grant Granted Jul 28, 2026
Patent 12669464
MODULARIZED INEXPENSIVE DETECTION OF CEREBRAL SPINAL FLUID FOR MEDICAL APPLICATIONS
6y 2m to grant Granted Jun 30, 2026
Patent 12669511
METABOLITES AS DIAGNOSTICS FOR AUTISM SPECTRUM DISORDER IN CHILDREN WITH GASTROINTESTINAL SYMPTOMS
4y 9m to grant Granted Jun 30, 2026
Patent 12618854
DIAGNOSTICS OF MILD OR ADVERSED PERIODONTITIS
5y 6m to grant Granted May 05, 2026
Patent 12498384
BIOMARKERS AND METHODS FOR EVALUATION AND TREATMENT OF EPILEPTIC VS NON-EPILEPTIC SEIZURES / NO SEIZURES / PSYCHOGENIC NON-EPILEPTIC SEIZURES
5y 0m to grant Granted Dec 16, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
32%
Grant Probability
77%
With Interview (+45.2%)
4y 0m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 76 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month